The number of research articles published on electrochemical nucleic acid-based biosensors has been increasing every year, however there is still no commercial DNA biosensor available. The major roadblock of the success of a commercial DNA biosensor can be the limitations arising from sample preparation, possible contaminations, or a need for an amplification step that may require laboratory settings. Also, the studies concentrated on the fully integrated DNA biosensing devices allowing for DNA extraction, PCR, or isothermal amplification (if needed) and electrochemical detection require more research and development. Notably, the devices with multiplexing capabilities for the detection of several genes simultaneously may lead a successful commercialisation path for future diagnostics. Finally, CRISPR-Cas, a technology which is gaining much attention in molecular biology in recent years, is a highly promising tool for the development of highly efficient sensing platforms. More development is, however, needed to meet all the ASSURED criteria (Affordable, Sensitive, Specific, User-friendly, Rapid, and robust, Equipment-free and Deliverable to end-users) required to successfully develop a device for POC application.